TTPH Tetraphase Pharmaceuticals Inc.

0.29
+0.01  (+5%)
Previous Close 0.28
Open 0.28
Price To Book 0.38
Market Cap 15,751,795
Shares 54,316,535
Volume 445,159
Short Ratio
Av. Daily Volume 632,612

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial also did not meet primary endpoints - noted February 13, 2018.
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
FDA approval announced August 27, 2018.
Eravacycline (TP-434) - IGNITE4
cIAI (complicated intra-abdominal infections)
Phase 1 trial complete.
TP-271
Community-acquired bacterial pneumonia (CABP)
Phase 1 bronchopulmonary disposition trial to be completed 2H 2019.
TP-6076

Latest News

  1. Edited Transcript of TTPH earnings conference call or presentation 8-Aug-19 8:30pm GMT
  2. Tetraphase Pharmaceuticals Inc (TTPH) Q2 2019 Earnings Call Transcript
  3. Tetraphase Pharmaceuticals (TTPH) Reports Q2 Loss, Lags Revenue Estimates
  4. Tetraphase Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate Developments
  5. Earnings Preview: Tetraphase Pharmaceuticals (TTPH) Q2 Earnings Expected to Decline
  6. New Studies Highlight Activity of XERAVA™ Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant Pathogens
  7. Edited Transcript of TTPH earnings conference call or presentation 8-May-19 8:30pm GMT
  8. Robbins Arroyo LLP: Tetraphase Pharmaceuticals, Inc. (TTPH) Accused of Misleading Shareholders
  9. What You Should Know About Tetraphase Pharmaceuticals, Inc.'s (NASDAQ:TTPH) Financial Strength
  10. The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes
  11. Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed at Maximizing XERAVA™ (Eravacycline) Commercial Opportunity
  12. Tetraphase Pharmaceuticals Announces New XERAVA™ (eravacycline) Data at the 39th Annual Surgical Infection Society Meeting
  13. Tetraphase Pharmaceuticals to Present Data at the 39th Annual Meeting of the Surgical Infection Society
  14. Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Misses Revenue Estimates
  15. Tetraphase: 1Q Earnings Snapshot
  16. Tetraphase Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Corporate Developments
  17. Edited Transcript of TTPH earnings conference call or presentation 14-Mar-19 8:30pm GMT
  18. Tetraphase Pharmaceuticals to Present Data at the 22nd Annual MAD-ID Meeting
  19. Tetraphase Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call